Sernova/SVA

Leading regenerative medicine company Sernova Biotherapeutics Inc. announced the appointment of a new Chairman of the Board with deep industry knowledge and experience.

Ross Haghighat "brings a wealth of financing and deal experience to Sernova's Board and leadership team, the company said in a release.

Haghighat has more than three decades of experience founding, funding, and scaling technology ventures in health care, Sernova said, adding that he is "known for his long-term strategic insights and the execution thereof, as evidenced in successfully driving multiple companies to achieve significant milestones and growth."

"We are thrilled to welcome Ross Haghighat as our new Chair of the Board," President and Chief Executive Officer Jonathnan Rigby said. "His deep industry knowledge and visionary leaders make him the perfect fit to guide Sernova as we advance our pipeline of transformative therapies. His appointment underscores our commitment to fulfilling our mission of bringing solutions to patients in need."

Haghighat said he was "honored to join Sernova and support its journey toward approval of its Cell Pouch bio-hybrid organ as a functional cure for TID."

"The company's pioneering work in cell therapy is truly inspiring," Haghighat continued. "I look forward to working with Jonathan, the Board, and the entire team to advance Sernova's mission and deliver on our goals."

Sernova is developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes. According to the company, its Board of Directors expressed unanimous support for the appointment of Haghighat.

New Name Reflects Business Better

In the release, Sernova also said it would change its name from Sernova Corp. to Sernova Biotherapeutics Inc. to "better communicate the nature of the business." No ticker symbol changes are expected.

Sernova also said the company will complete the continuance of its corporate jurisdiction into British Columbia and become a corporation existing under the Business Corporations Act of British Columbia kknstead of the Canada Business Corporations Act. This change was approved by shareholders with a special resolution at the company's annual and special general meeting on January 10.

Process Forms a Vascularized Organ-Like Environment

Sernova's Cell Pouch is a vascularized cell-carrying bio-hybrid organ implanted in the human body. In an ongoing U.S. Phase 1/2 clinical trial, Sernova is assessing the treatment of patients with insulin-dependent type 1 diabetes and severe hypoglycemic episodes with donor islets implanted within the subcutaneous Cell Pouch. To protect cells from immune attack, patients are provided with an optimized immunosuppression protocol.

To deliver treatment, the Cell Pouch is pre-implanted under the skin between the deep subcutaneous muscle and the fascia, an area rich in blood vessels. The bio-hybrid organ is uniquely designed with pores into which vascularized tissue grows over several weeks post-implantation, forming a vascularized organ-like environment believed to be critical for the long-term survival and function of therapeutic cells. Following the development of the organ-like environment, the cells are transplanted into its containment channels and engrafted into the surrounding microvessel-rich environment, where they read blood sugar levels and release insulin and other hormones to naturally control blood glucose levels.

Clinical trial data so far have shown the Cell Pouch to be safe and well tolerated and the treatment to be effective, reported Dr. Joseph Pantginis, H.C. Wainwright & Co. analyst, in a September research report.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a September research report.

In collaboration with Evotec AG (EVTCY:OTCPK), Sernova is also developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Technical Analyst Clive Maund wrote recently.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," Maund wrote. "If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive."

Nations Spend as Much as 9% of Health Budget on Disease

Diabetes affects 537 million globally and is expected to affect 643 million people by 2030, the International Diabetes Foundation reported. Nations spend as much as 9% of their health budget on the disease, and about 10% of diabetes patients are insulin-dependent.

Grand View Research reported that the global market size for diabetes devices was estimated at about US$30.31 billion in 2023 and is projected to grow at a CAGR of 7.45% from 2024 to 2030.

The global live cell encapsulation market encompasses drug delivery, regenerative medicine, and cell transplantation. It is expected to continue growing through at least 2030, according to Grand View. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, the market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Grand View noted that market growth is expected to be driven by the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

Ownership and Share Structure

According to Refinitiv, about 4.1% of the company is held by insiders and management, and approximately 0.05% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 3.97%, Chief Financial Officer James Parsons with 0.12%, CATAM Asset Management AG with 0.05%, and Chief Business Officer Modestus Obochi with 0.02%.

Sernova has 328.48 million outstanding shares and 315.01 million free float traded shares.

Its market cap is CA$69.32 million. It trades in a 52-week range CA$0.70 and CA$0.17.